399 related articles for article (PubMed ID: 16282837)
1. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
2. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.
Wohlreich MM; Mallinckrodt CH; Watkin JG; Wilson MG; Greist JH; Delgado PL; Fava M
Ann Clin Psychiatry; 2005; 17(4):259-68. PubMed ID: 16402760
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
7. Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.
Dunner DL; Wohlreich MM; Mallinckrodt CH; Watkin JG; Fava M
Curr Ther Res Clin Exp; 2005 Nov; 66(6):522-40. PubMed ID: 24678074
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
12. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
